The role of matrix metalloproteinases in pathogenesis, diagnostics, and treatment of human prostate cancer

[1] Aaron L, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol Clin North Am. 2016; 43: 279–288. AaronL FrancoOE HaywardSW Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia Urol Clin North Am 2016 43 279 288 Search in Google Scholar

[2] Toivanen R, Shen MM. Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. Development. 2017; 144: 1382–1398. ToivanenR ShenMM Prostate organogenesis: tissue induction, hormonal regulation and cell type specification Development 2017 144 1382 1398 Search in Google Scholar

[3] Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim-Biophys Acta. 2010; 1803: 55–71. BrewK NagaseH The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity Biochim-Biophys Acta 2010 1803 55 71 Search in Google Scholar

[4] Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018; 17: 1147–1155. WinerA AdamsS MignattiP Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes Mol Cancer Ther 2018 17 1147 1155 Search in Google Scholar

[5] Wiśniowski T, Bryda J, Kurzepa J, Wątroba S. The role of matrix metalloproteinases in pathogenesis of human bladder cancer. Acta Biochim Pol. 2021; 68: 547–555. WiśniowskiT BrydaJ KurzepaJ WątrobaS The role of matrix metalloproteinases in pathogenesis of human bladder cancer Acta Biochim Pol 2021 68 547 555 Search in Google Scholar

[6] Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer. J Clin. 2016; 66: 7–30. SiegelRL MillerKD JemalA Cancer statistics CA Cancer. J Clin. 2016 66 7 30 Search in Google Scholar

[7] Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. Prostate cancer. Lancet. 2016; 387: 70–82. AttardG ParkerC EelesRA SchröderF TomlinsSA TannockI DrakeCG de BonoJS Prostate cancer Lancet 2016 387 70 82 Search in Google Scholar

[8] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: 359–386. FerlayJ SoerjomataramI DikshitR EserS MathersC RebeloM ParkinDM FormanD BrayF Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 2015 136 359 386 Search in Google Scholar

[9] Białkowska K, Marciniak W, Muszyńska M, Baszuk P, Gupta S, Jaworska-Bieniek K, Sukiennicki G, Durda K, Gromowski T, Prajzendanc K, et al. Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. PLoS One. 2018; 13: e0201065. BiałkowskaK MarciniakW MuszyńskaM BaszukP GuptaS Jaworska-BieniekK SukiennickiG DurdaK GromowskiT PrajzendancK Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population PLoS One 2018 13 e0201065 Search in Google Scholar

[10] Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer. 2015; 137: 1749–1757. BellKJ Del MarC WrightG DickinsonJ GlasziouP Prevalence of incidental prostate cancer: A systematic review of autopsy studies Int J Cancer 2015 137 1749 1757 Search in Google Scholar

[11] Pikala M, Burzyńska M, Maniecka-Bryła I. Epidemiology of mortality due to prostate cancer in Poland, 2000–2015. Int J Environ Res Public Health. 2019; 16: 2881. PikalaM BurzyńskaM Maniecka-BryłaI Epidemiology of mortality due to prostate cancer in Poland, 2000–2015 Int J Environ Res Public Health 2019 16 2881 Search in Google Scholar

[12] Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006; 11: 1388–1413. HsingAW ChokkalingamAP Prostate cancer epidemiology Front Biosci 2006 11 1388 1413 Search in Google Scholar

[13] Dulińska-Litewka J, Hałubiec P, Łazarczyk A, Szafrański O, Sharoni Y, McCubrey JA, Gąsiorkiewicz B, Bohn T. Recent progress in discovering the role of carotenoids and metabolites in prostatic physiology and pathology—A review—part II: carotenoids in the human studies. Antioxidants. 2021; 10: 319. Dulińska-LitewkaJ HałubiecP ŁazarczykA SzafrańskiO SharoniY McCubreyJA GąsiorkiewiczB BohnT Recent progress in discovering the role of carotenoids and metabolites in prostatic physiology and pathology—A review—part II: carotenoids in the human studies Antioxidants 2021 10 319 Search in Google Scholar

[14] Dulińska-Litewka J, Sharoni Y, Hałubiec P, Łazarczyk A, Szafrański O, McCubrey JA, Gąsiorkiewicz B, Laidler P, Bohn T. Recent progress in discovering the role of carotenoids and their metabolites in Prostatic physiology and pathology with a focus on prostate cancer—A review—part I: Molecular mechanisms of carotenoid action. Antioxidants. 2021; 10: 585. Dulińska-LitewkaJ SharoniY HałubiecP ŁazarczykA SzafrańskiO McCubreyJA GąsiorkiewiczB LaidlerP BohnT Recent progress in discovering the role of carotenoids and their metabolites in Prostatic physiology and pathology with a focus on prostate cancer—A review—part I: Molecular mechanisms of carotenoid action Antioxidants 2021 10 585 Search in Google Scholar

[15] Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019; 76: 340–351. TurkbeyB RosenkrantzAB HaiderMA PadhaniAR VilleirsG MacuraKJ TempanyCM ChoykePL CornudF MargolisDJ Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2 Eur Urol 2019 76 340 351 Search in Google Scholar

[16] Bhavsar A, Verma S. Anatomic imaging of the prostate. Biomed Res Int. 2014; 2014: 728539. BhavsarA VermaS Anatomic imaging of the prostate Biomed Res Int 2014 2014 728539 Search in Google Scholar

[17] Van der Kwast T, Bubendorf L, Mazerolles C, Raspollini MR, Van Leenders GJ, Pihl CG, Kujala P. Pathology Committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Virchows Arch. 2013; 463: 367–377. Van der KwastT BubendorfL MazerollesC RaspolliniMR Van LeendersGJ PihlCG KujalaP Pathology Committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC) Virchows Arch 2013 463 367 377 Search in Google Scholar

[18] D’Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999; 17: 168–172. D’AmicoAV WhittingtonR MalkowiczSB FonduruliaJ ChenMH KaplanI BeardCJ TomaszewskiJE RenshawAA WeinA Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer J Clin Oncol 1999 17 168 172 Search in Google Scholar

[19] Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, Lukka H. Genitourinary radiation oncologists of canada. Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J. 2012; 6: 121–127. RodriguesG WardeP PicklesT CrookJ BrundageM SouhamiL LukkaH Genitourinary radiation oncologists of canada. Pre-treatment risk stratification of prostate cancer patients: A critical review Can Urol Assoc J 2012 6 121 127 Search in Google Scholar

[20] Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994; 151: 1283–1290. CatalonaWJ RichieJP AhmannFR HudsonMA ScardinoPT FlaniganRC DeKernionJB RatliffTL KavoussiLR DalkinBL Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men J Urol 1994 151 1283 1290 Search in Google Scholar

[21] Loeb S, Catalona WJ. The prostate health index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014; 6: 74–77. LoebS CatalonaWJ The prostate health index: a new test for the detection of prostate cancer Ther Adv Urol 2014 6 74 77 Search in Google Scholar

[22] Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2015; 68: 139–146. NordströmT VickersA AsselM LiljaH GrönbergH EklundM Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer Eur Urol 2015 68 139 146 Search in Google Scholar

[23] Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008; 179: 1587–1592. DerasIL AubinSM BlaseA DayJR KooS PartinAW EllisWJ MarksLS FradetY RittenhouseH PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 2008 179 1587 1592 Search in Google Scholar

[24] Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016; 70: 740–748. Van NesteL HendriksRJ DijkstraS TrooskensG CornelEB JanninkSA de JongH HesselsD SmitFP MelchersWJ Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score Eur Urol 2016 70 740 748 Search in Google Scholar

[25] Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014; 192: 1081–1087. PartinAW Van NesteL KleinEA MarksLS GeeJR TroyerDA Rieger-ChristK JonesJS Magi-GalluzziC MangoldLA Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies J Urol 2014 192 1081 1087 Search in Google Scholar

[26] Wątroba S, Wiśniowski T, Bryda J, Kurzepa J. Characteristics of matrix metalloproteinases and their role in embryogenesis of the mammalian respiratory system. PostepyHig Med Dosw. 2021; 75: 24–34. WątrobaS WiśniowskiT BrydaJ KurzepaJ Characteristics of matrix metalloproteinases and their role in embryogenesis of the mammalian respiratory system PostepyHig Med Dosw 2021 75 24 34 Search in Google Scholar

[27] Wątroba S, Kocot J, Bryda J, Kurzepa J. Serum activity of MMP-2 and MMP-9 and stromielisin-1 concentration as predictors in the pathogenesis of bronchopulmonary dysplasia in preterm neonates. PostepyHig Med Dosw. 2019; 73: 703–712. WątrobaS KocotJ BrydaJ KurzepaJ Serum activity of MMP-2 and MMP-9 and stromielisin-1 concentration as predictors in the pathogenesis of bronchopulmonary dysplasia in preterm neonates PostepyHig Med Dosw 2019 73 703 712 Search in Google Scholar

[28] Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. 2014; 71: 659–672. RiesC Cytokine functions of TIMP-1 Cell Mol Life Sci 2014 71 659 672 Search in Google Scholar

[29] Woolley DE, Roberts DR, Evanson JM. Inhibition of human collagenase activity by a small molecular weight serum protein. Biochem-Biophys Res Commun. 1975; 66: 747–754. WoolleyDE RobertsDR EvansonJM Inhibition of human collagenase activity by a small molecular weight serum protein Biochem-Biophys Res Commun 1975 66 747 754 Search in Google Scholar

[30] Murphy G, Houbrechts A, Cockett MI, Williamson RA, O’Shea M, Docherty AJ. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry. 1991; 30: 8097–8102. MurphyG HoubrechtsA CockettMI WilliamsonRA O’SheaM DochertyAJ The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity Biochemistry 1991 30 8097 8102 Search in Google Scholar

[31] Arza B, De Maeyer M, Félez J, Collen D, Lijnen HR. Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3). Eur J Biochem. 2001; 268: 826–831. ArzaB De MaeyerM FélezJ CollenD LijnenHR Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3) Eur J Biochem 2001 268 826 831 Search in Google Scholar

[32] Janowska-Wieczorek A, Marquez LA, Dobrowsky A, Ratajczak MZ, Cabuhat ML. Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. Exp Hematol. 2000; 28: 1274–1285. Janowska-WieczorekA MarquezLA DobrowskyA RatajczakMZ CabuhatML Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines Exp Hematol 2000 28 1274 1285 Search in Google Scholar

[33] Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. BiochimBiophys Acta. 2000; 1477: 267–283. BrewK DinakarpandianD NagaseH Tissue inhibitors of metalloproteinases: evolution, structure and function BiochimBiophys Acta 2000 1477 267 283 Search in Google Scholar

[34] Gasson JC, Golde DW, Kaufman SE, Westbrook CA, Hewick RM, Kaufman RJ, Wong GG, Temple PA, Leary AC, Brown EL, et al. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature. 1985; 315: 768–771. GassonJC GoldeDW KaufmanSE WestbrookCA HewickRM KaufmanRJ WongGG TemplePA LearyAC BrownEL Molecular characterization and expression of the gene encoding human erythroid-potentiating activity Nature 1985 315 768 771 Search in Google Scholar

[35] Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit. Rev. Oncol Hematol. 2004; 49: 187–198. LambertE DasséE HayeB PetitfrèreE TIMPs as multifacial proteins Crit. Rev. Oncol Hematol. 2004 49 187 198 Search in Google Scholar

[36] Ozenci V, Rinaldi L, Teleshova N, Matusevicius D, Kivisäkk P, Kouwenhoven M, Link H. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J Autoimmun. 1999; 12: 297–303. OzenciV RinaldiL TeleshovaN MatuseviciusD KivisäkkP KouwenhovenM LinkH Metalloproteinases and their tissue inhibitors in multiple sclerosis J Autoimmun 1999 12 297 303 Search in Google Scholar

[37] Stetler-Stevenson WG, Bersch N, Golde DW. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett. 1992; 296: 231–234. Stetler-StevensonWG BerschN GoldeDW Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity FEBS Lett 1992 296 231 234 Search in Google Scholar

[38] Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci. 1994; 107: 2373–2379. HayakawaT YamashitaK OhuchiE ShinagawaA Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2) J Cell Sci 1994 107 2373 2379 Search in Google Scholar

[39] Wang T, Yamashita K, Iwata K, Hayakawa T. Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways. BiochemBiophys Res Commun. 2002; 296: 201–205. WangT YamashitaK IwataK HayakawaT Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways BiochemBiophys Res Commun 2002 296 201 205 Search in Google Scholar

[40] Jotwani R, Eswaran SV, Moonga S, Cutler CW. MMP-9/TIMP-1 imbalance induced in human dendritic cells by Porphyromonasgingivalis. FEMS Immunol Med Microbiol. 2010; 58: 314–321. JotwaniR EswaranSV MoongaS CutlerCW MMP-9/TIMP-1 imbalance induced in human dendritic cells by Porphyromonasgingivalis FEMS Immunol Med Microbiol 2010 58 314 321 Search in Google Scholar

[41] Kurzepa J, Szczepanska-Szerej A, Stryjecka-Zimmer M, Malecka-Massalska T, Stelmasiak Z. Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke. Folia Biol (Praha). 2006; 52: 181–183. KurzepaJ Szczepanska-SzerejA Stryjecka-ZimmerM Malecka-MassalskaT StelmasiakZ Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke Folia Biol (Praha) 2006 52 181 183 Search in Google Scholar

[42] Reis ST, Pontes-Junior J, Antunes AA, de Sousa-Canavez JM, Dall’Oglio MF, Passerotti CC, Abe DK, Crippa A, da Cruz JA, Timoszczuk LM, et al. MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer. Int J Biol Markers. 2011; 26: 255–261. ReisST Pontes-JuniorJ AntunesAA de Sousa-CanavezJM Dall’OglioMF PasserottiCC AbeDK CrippaA da CruzJA TimoszczukLM MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer Int J Biol Markers 2011 26 255 261 Search in Google Scholar

[43] Roy R, Morad G, Jedinak A, Moses MA. Metalloproteinases and their roles in human cancer. Anat Rec. 2020; 303: 1557–1572. RoyR MoradG JedinakA MosesMA Metalloproteinases and their roles in human cancer Anat Rec 2020 303 1557 1572 Search in Google Scholar

[44] Turunen SP, Tatti-Bugaeva O, Lehti K. Membrane-type matrix metalloproteases as diverse effectors of cancer progression. BiochimBiophys Acta Mol Cell Res. 2017; 1864: 1974–1988. TurunenSP Tatti-BugaevaO LehtiK Membrane-type matrix metalloproteases as diverse effectors of cancer progression BiochimBiophys Acta Mol Cell Res 2017 1864 1974 1988 Search in Google Scholar

[45] Noë V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 2001; 114: 111–118. NoëV FingletonB JacobsK CrawfordHC VermeulenS SteelantW BruyneelE MatrisianLM MareelM Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1 J Cell Sci 2001 114 111 118 Search in Google Scholar

[46] Sakamoto T, Seiki M. A membrane protease regulates energy production in macrophages by activating hypoxia-inducible factor-1 via a non-proteolytic mechanism. J Biol Chem. 2010; 285: 29951–29964. SakamotoT SeikiM A membrane protease regulates energy production in macrophages by activating hypoxia-inducible factor-1 via a non-proteolytic mechanism J Biol Chem 2010 285 29951 29964 Search in Google Scholar

[47] Nowak E, Bednarek I. Epithelial to mesenchymal transition in carcinogenesis [Przejścieepitelialno-mezenchymalne w procesachnowotworzenia]. Post Biol Kom. 2018; 3: 223–236. NowakE BednarekI Epithelial to mesenchymal transition in carcinogenesis [Przejścieepitelialno-mezenchymalne w procesachnowotworzenia] Post Biol Kom 2018 3 223 236 Search in Google Scholar

[48] Dudzik P, Trojan SE, Ostrowska B, Zemanek G, Dulińska-Litewka J, Laidler P, Kocemba-Pilarczyk KA. The epigenetic modifier 5-aza-2-deoxycytidine triggers the expression of CD146 gene in prostate cancer cells. Anticancer Res. 2019; 39: 2395–2403. DudzikP TrojanSE OstrowskaB ZemanekG Dulińska-LitewkaJ LaidlerP Kocemba-PilarczykKA The epigenetic modifier 5-aza-2-deoxycytidine triggers the expression of CD146 gene in prostate cancer cells Anticancer Res 2019 39 2395 2403 Search in Google Scholar

[49] Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol. 1997; 139: 1861–1872. LochterA GalosyS MuschlerJ FreedmanN WerbZ BissellMJ Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells J Cell Biol 1997 139 1861 1872 Search in Google Scholar

[50] Leroyer AS, Blin MG, Bachelier R, Bardin N, Blot-Chabaud M, Dignat-George F. CD146 (Cluster of Differentiation 146). ArteriosclerThrombVasc Biol. 2019; 39: 1026–1033. LeroyerAS BlinMG BachelierR BardinN Blot-ChabaudM Dignat-GeorgeF CD146 (Cluster of Differentiation 146) ArteriosclerThrombVasc Biol 2019 39 1026 1033 Search in Google Scholar

[51] Liu C, Jiang S, Xie H, Jia H, Li R, Zhang K, Wang N, Lin P, Yu X. Long non-coding RNA AC245100.4 contributes to prostate cancer migration via regulating PAR2 and activating p38-MAPK pathway. Med Oncol. 2022; 39: 94. LiuC JiangS XieH JiaH LiR ZhangK WangN LinP YuX Long non-coding RNA AC245100.4 contributes to prostate cancer migration via regulating PAR2 and activating p38-MAPK pathway Med Oncol 2022 39 94 Search in Google Scholar

[52] Han Z, Mo R, Cai S, Feng Y, Tang Z, Ye J, Liu R, Cai Z, Zhu X, Deng Y, et al. Differential expression of E2F transcription factors and their functional and prognostic roles in human prostate cancer. Front Cell Dev Biol. 2022; 10: 831329. HanZ MoR CaiS FengY TangZ YeJ LiuR CaiZ ZhuX DengY Differential expression of E2F transcription factors and their functional and prognostic roles in human prostate cancer Front Cell Dev Biol 2022 10 831329 Search in Google Scholar

[53] Chen B, Li R, Hernandez SC, Hanna A, Su K, Shinde AV, Frangogiannis NG. Differential effects of Smad2 and Smad3 in regulation of macrophage phenotype and function in the infarcted myocardium. J Mol Cell Cardiol. 2022; 171: 1–15. ChenB LiR HernandezSC HannaA SuK ShindeAV FrangogiannisNG Differential effects of Smad2 and Smad3 in regulation of macrophage phenotype and function in the infarcted myocardium J Mol Cell Cardiol 2022 171 1 15 Search in Google Scholar

[54] Karmakar D, Maity J, Mondal P, Shyam Chowdhury P, Sikdar N, Karmakar P, Das C, Sengupta S. E2F5 promotes prostate cancer cell migration and invasion through regulation of TFPI2, MMP-2 and MMP-9. Carcinogenesis. 2020; 41: 1767–1780. KarmakarD MaityJ MondalP Shyam ChowdhuryP SikdarN KarmakarP DasC SenguptaS E2F5 promotes prostate cancer cell migration and invasion through regulation of TFPI2, MMP-2 and MMP-9 Carcinogenesis 2020 41 1767 1780 Search in Google Scholar

[55] Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, et al. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol. 2013; 133: 1278–1285. Lo NigroC WangH McHughA LattanzioL MatinR HarwoodC SyedN HatzimichaelE BriasoulisE MerlanoM Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma J Invest Dermatol 2013 133 1278 1285 Search in Google Scholar

[56] Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol. 2013; 13: 649–665. KhokhaR MurthyA WeissA Metalloproteinases and their natural inhibitors in inflammation and immunity Nat Rev Immunol 2013 13 649 665 Search in Google Scholar

[57] Zhao L, Li C, Liu F, Zhao Y, Liu J, Hua Y, Liu J, Huang J, Ge C. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther. 2017; 10: 2115–2126. ZhaoL LiC LiuF ZhaoY LiuJ HuaY LiuJ HuangJ GeC A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway Onco Targets Ther 2017 10 2115 2126 Search in Google Scholar

[58] Rydlova M, Holubec L Jr, Ludvikova M Jr, Kalfert D, Franekova J, Povysil C, Ludvikova M. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res. 2008; 28: 1389–1397. RydlovaM HolubecLJr LudvikovaMJr KalfertD FranekovaJ PovysilC LudvikovaM Biological activity and clinical implications of the matrix metalloproteinases Anticancer Res 2008 28 1389 1397 Search in Google Scholar

[59] Vizoso FJ, González LO, Corte MD, Rodríguez JC, Vázquez J, Lamelas ML, Junquera S, Merino AM, García-Muñiz JL. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007; 96: 903–911. VizosoFJ GonzálezLO CorteMD RodríguezJC VázquezJ LamelasML JunqueraS MerinoAM García-MuñizJL Study of matrix metalloproteinases and their inhibitors in breast cancer Br J Cancer 2007 96 903 911 Search in Google Scholar

[60] Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, Mazzarino MC. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res. 2005; 33: 44–50. MorgiaG FalsaperlaM MalaponteG MadoniaM IndelicatoM TravaliS MazzarinoMC Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer Urol Res 2005 33 44 50 Search in Google Scholar

[61] Anteby EY, Greenfield C, Natanson-Yaron S, Goldman-Wohl D, Hamani Y, Khudyak V, Ariel I, Yagel S. Vascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and -10 stimulate trophoblast plasminogen activator system and metalloproteinase-9. Mol Hum Reprod. 2004; 10: 229–235. AntebyEY GreenfieldC Natanson-YaronS Goldman-WohlD HamaniY KhudyakV ArielI YagelS Vascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and -10 stimulate trophoblast plasminogen activator system and metalloproteinase-9 Mol Hum Reprod 2004 10 229 235 Search in Google Scholar

[62] Brauer PR. MMPs-role in cardiovascular development and disease. Front Biosci. 2006; 11: 447–478. BrauerPR MMPs-role in cardiovascular development and disease Front Biosci 2006 11 447 478 Search in Google Scholar

[63] Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev. 2007; 87: 69–98. GreenleeKJ WerbZ KheradmandF Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted Physiol Rev 2007 87 69 98 Search in Google Scholar

[64] Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res. 1998; 55: 29–42. LamoreauxWJ FitzgeraldME ReinerA HastyKA CharlesST Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro Microvasc Res 1998 55 29 42 Search in Google Scholar

[65] Ok Atılgan A, Özdemir BH, YılmazAkçay E, Tepeoğlu M, Börcek P, Dirim A. Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma. Ann DiagnPathol. 2020; 45: 151480. Ok AtılganA ÖzdemirBH YılmazAkçayE TepeoğluM BörcekP DirimA Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma Ann DiagnPathol 2020 45 151480 Search in Google Scholar

[66] Defilippi P, Di Stefano P, Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 2006; 16: 257–263. DefilippiP Di StefanoP CabodiS p130Cas: a versatile scaffold in signaling networks Trends Cell Biol 2006 16 257 263 Search in Google Scholar

[67] Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 2008; 40: 2707–2719. RamosJW The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells Int J Biochem Cell Biol 2008 40 2707 2719 Search in Google Scholar

[68] Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010; 11: 329–341. VanhaesebroeckB Guillermet-GuibertJ GrauperaM BilangesB The emerging mechanisms of isoform-specific PI3K signalling Nat Rev Mol Cell Biol 2010 11 329 341 Search in Google Scholar

[69] Kumar AA, Buckley BJ, Ranson M. The urokinase plasminogen activation system in pancreatic cancer: prospective diagnostic and therapeutic targets. Biomolecules. 2022; 12: 152. KumarAA BuckleyBJ RansonM The urokinase plasminogen activation system in pancreatic cancer: prospective diagnostic and therapeutic targets Biomolecules 2022 12 152 Search in Google Scholar

[70] Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. ArteriosclerThrombVasc Biol. 2001; 21: 1104–1117. PepperMS Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis ArteriosclerThrombVasc Biol 2001 21 1104 1117 Search in Google Scholar

[71] Oblander SA, Zhou Z, Gálvez BG, Starcher B, Shannon JM, Durbeej M, Arroyo AG, Tryggvason K, Apte SS. Distinctive functions of membrane type 1 matrix-metalloprotease (MT1-MMP or MMP-14) in lung and submandibular gland development are independent of its role in pro-MMP-2 activation. Dev Biol. 2005; 277: 255–269. OblanderSA ZhouZ GálvezBG StarcherB ShannonJM DurbeejM ArroyoAG TryggvasonK ApteSS Distinctive functions of membrane type 1 matrix-metalloprotease (MT1-MMP or MMP-14) in lung and submandibular gland development are independent of its role in pro-MMP-2 activation Dev Biol 2005 277 255 269 Search in Google Scholar

[72] Kheradmand F, Rishi K, Werb Z. Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2. J Cell Sci. 2002; 115: 839–848. KheradmandF RishiK WerbZ Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2 J Cell Sci 2002 115 839 848 Search in Google Scholar

[73] Ganser GL, Stricklin GP, Matrisian LM. EGF and TGF alpha influence in vitro lung development by the induction of matrix-degrading metalloproteinases. Int J Dev Biol. 1991; 35: 453–461. GanserGL StricklinGP MatrisianLM EGF and TGF alpha influence in vitro lung development by the induction of matrix-degrading metalloproteinases Int J Dev Biol 1991 35 453 461 Search in Google Scholar

[74] Bahmad HF, Jalloul M, Azar J, Moubarak MM, Samad TA, Mukherji D, Al-Sayegh M, Abou-Kheir W. Tumor microenvironment in prostate cancer: toward identification of novel molecular biomarkers for diagnosis, prognosis, and therapy development. Front Genet. 2021; 12: 652747. BahmadHF JalloulM AzarJ MoubarakMM SamadTA MukherjiD Al-SayeghM Abou-KheirW Tumor microenvironment in prostate cancer: toward identification of novel molecular biomarkers for diagnosis, prognosis, and therapy development Front Genet 2021 12 652747 Search in Google Scholar

[75] Ozden F, Saygin C, Uzunaslan D, Onal B, Durak H, Aki H. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. J Cancer Res Clin Oncol. 2013; 139: 1373–1382. OzdenF SayginC UzunaslanD OnalB DurakH AkiH Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival J Cancer Res Clin Oncol 2013 139 1373 1382 Search in Google Scholar

[76] Nonsrijun N, Mitchai J, Brown K, Leksomboon R, Tuamsuk P. Overexpression of matrix metalloproteinase 11 in Thai prostatic adenocarcinoma is associated with poor survival. Asian Pac J Cancer Prev. 2013; 14: 3331–3335. NonsrijunN MitchaiJ BrownK LeksomboonR TuamsukP Overexpression of matrix metalloproteinase 11 in Thai prostatic adenocarcinoma is associated with poor survival Asian Pac J Cancer Prev 2013 14 3331 3335 Search in Google Scholar

[77] Reis ST, Viana NI, Iscaife A, Pontes-Junior J, Dip N, Antunes AA, Guimarães VR, Santana I, Nahas WC, Srougi M, et al. Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer. Int Braz J Urol. 2015; 41: 1088–1095. ReisST VianaNI IscaifeA Pontes-JuniorJ DipN AntunesAA GuimarãesVR SantanaI NahasWC SrougiM Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer Int Braz J Urol 2015 41 1088 1095 Search in Google Scholar

[78] Baspinar S, Bircan S, Ciris M, Karahan N, Bozkurt KK. Expression of NGF, GDNF and MMP-9 in prostate carcinoma. Pathol Res Pract. 2017; 213: 483–489. BaspinarS BircanS CirisM KarahanN BozkurtKK Expression of NGF, GDNF and MMP-9 in prostate carcinoma Pathol Res Pract 2017 213 483 489 Search in Google Scholar

[79] Szarvas T, Csizmarik A, Váradi M, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Tschirdewahn S, Shariat SF, et al. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy. Urol Oncol. 2021; 39: 296.e11–296.e19. SzarvasT CsizmarikA VáradiM FazekasT HüttlA NyirádyP HadaschikB GrünwaldV TschirdewahnS ShariatSF The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy Urol Oncol 2021 39 296.e11 296.e19 Search in Google Scholar

[80] Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. PharmacolTher. 1997; 75: 69–75. RasmussenHS McCannPP Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat PharmacolTher 1997 75 69 75 Search in Google Scholar

[81] Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer Res. 2005; 11: 4437–4443. RosenbaumE ZahurakM SinibaldiV CarducciMA PiliR LauferM DeWeeseTL EisenbergerMA Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial Clin Cancer Res 2005 11 4437 4443 Search in Google Scholar

[82] Liang M, Wang J, Wu C, Wu M, Hu J, Dai J, Ruan H, Xiong S, Dong C. Targeting matrix metalloproteinase MMP3 greatly enhances oncolytic virus mediated tumor therapy. Translational Oncology. 2021; 14: 101221. LiangM WangJ WuC WuM HuJ DaiJ RuanH XiongS DongC Targeting matrix metalloproteinase MMP3 greatly enhances oncolytic virus mediated tumor therapy Translational Oncology 2021 14 101221 Search in Google Scholar

[83] Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015; 373: 2005–2014. SparanoJA GrayRJ MakowerDF PritchardKI AlbainKS HayesDF GeyerCEJr DeesEC PerezEA OlsonJA Prospective validation of a 21-gene expression assay in breast cancer N Engl J Med 2015 373 2005 2014 Search in Google Scholar

[84] Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2017; 17: 38–53. JacksonHW DefamieV WaterhouseP KhokhaR TIMPs: versatile extracellular regulators in cancer Nat Rev Cancer 2017 17 38 53 Search in Google Scholar

[85] Gobin E, Bagwell K, Wagner J, Mysona D, Sandirasegarane S, Smith N, Bai S, Sharma A, Schleifer R, She JX. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. BMC Cancer. 2019; 19: 581. GobinE BagwellK WagnerJ MysonaD SandirasegaraneS SmithN BaiS SharmaA SchleiferR SheJX A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential BMC Cancer 2019 19 581 Search in Google Scholar

[86] Levin M, Udi Y, Solomonov I, Sagi I. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects. BiochimBiophys Acta Mol Cell Res. 2017; 1864: 1927–1939. LevinM UdiY SolomonovI SagiI Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects BiochimBiophys Acta Mol Cell Res 2017 1864 1927 1939 Search in Google Scholar